Press release
Diabetic Retinopathy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Diabetic Retinopathy Treatment Landscape. Click here to read more @ Diabetic Retinopathy Pipeline Outlook [https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Diabetic Retinopathy Pipeline Report
* In March 2025:- Vantage Biosciences Ltd announced a study to evaluate the Efficacy and Safety of Orally Administered VX-01 in Diabetic Retinopathy of Non-Proliferative Type (NPDR).
* In March 2025:- Invirsa Inc. announced a phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR [Part 1] and during an 8-week dosing period in subjects with center-involved DME (CIDME) associated with NPDR [Part 1].
* In March 2025:- Incepta Pharmaceuticals Ltd conducted a study to to Compare Efficacy & Safety Between Ranibizumab 10mg/ml Injection of Incepta and Lucentis in Patients With Diabetic Macular Edema by ITV Injection.
* In March 2025:- EyePoint Pharmaceuticals Inc. announced a study of Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME).
* DelveInsight's Diabetic Retinopathy pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Diabetic Retinopathy treatment.
* The leading Diabetic Retinopathy Companies such as Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim , and others.
* Promising Diabetic Retinopathy Pipeline Therapies such as Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine , and others.
Discover groundbreaking developments in Diabetic Retinopathy therapies! Gain in-depth knowledge of key Diabetic Retinopathy clinical trials, emerging drugs, and market opportunities @ Diabetic Retinopathy Clinical Trials Assessment [https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Diabetic Retinopathy Emerging Drugs Profile
* Tarcocimab tedromer: Kodiak Sciences
Tarcocimab is an investigational anti-VEGF therapy built on Kodiak's proprietary Antibody Biopolymer Conjugate (""ABC"") Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing available agents. Kodiak's objective with tarcocimab is to enable earlier treatment and prevention of vision loss for patients with diabetic retinopathy and to develop a new durability agent to improve outcomes for patients with retinal vascular diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of diabetic retinopathy.
* OTT166: Ocuterra Therapeutics
Nesvategrast (OTT166) is an investigational, novel, patented, potent and selective small molecule RGD integrin inhibitor designed with purpose engineering to have an optimum balance of physiochemical properties to allow it to distribute to the retina in high concentrations after topical (eye drop) administration to the eye. In preclinical studies, nesvategrast selectively inhibited key RGD integrin subtypes, including v3, to regulate cellular responses to VEGF and other growth factors known to contribute to development and progression of diabetic retinopathy and other ocular diseases. In early clinical trials in patients with diabetic retinal disease, nesvategrast eye drops have demonstrated preliminary evidence of tolerability and biological activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diabetic retinopathy.
* APX3330: Apexian Pharmaceuticals
APX3330 is a first-in-class, small molecule, oral inhibitor of the transcription factor regulator Ref-1 (reduction-oxidation effector factor-1). With a novel dual mechanism of action, APX3330 blocks the downstream pathways those involving angiogenesis (VEGF) and inflammation (NFkB) to decrease abnormal activation of both angiogenesis, and of inflammatory pathways that are implicated across several ocular diseases, including DR, DME, and age-related macular degeneration (AMD). APX3330 has shown a favorable safety and tolerability profile in 12 clinical trials conducted in healthy, hepatitis, cancer, and diabetic subjects. Currently, the drug is in Phase II stage of its clinical trial for the treatment of diabetic retinopathy.
OTX-TKI: Ocular Therapeutix
OTX-TKI is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetic retinopathy.
The Diabetic Retinopathy Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Retinopathy with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Retinopathy Treatment.
* Diabetic Retinopathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Diabetic Retinopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Retinopathy market
Stay informed about the Diabetic Retinopathy pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Diabetic Retinopathy Unmet Needs [https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Diabetic Retinopathy Companies
Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Diabetic Retinopathy Pipeline Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Transform your understanding of the Diabetic Retinopathy Pipeline! See the latest progress in drug development and clinical research @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Diabetic Retinopathy Pipeline Report
* Coverage- Global
* Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim , and others.
* Diabetic Retinopathy Pipeline Therapies- Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine , and others.
* Diabetic Retinopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Diabetic Retinopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Dive deep into rich insights for new drugs for Diabetic Retinopathy Treatment, Visit @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspective [https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Diabetic Retinopathy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Diabetic Retinopathy- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* KSI-301: Kodiak Sciences
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* RGX 314: Regenxbio Inc
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* OTX-TKI: Ocular Therapeutix
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Diabetic Retinopathy Key Companies
* Diabetic Retinopathy Key Products
* Diabetic Retinopathy- Unmet Needs
* Diabetic Retinopathy- Market Drivers and Barriers
* Diabetic Retinopathy- Future Perspectives and Conclusion
* Diabetic Retinopathy Analyst Views
* Diabetic Retinopathy Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diabetic-retinopathy-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/diabetic-retinopathy-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Retinopathy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3913362 • Views: …
More Releases from ABNewswire
NanoViricides Reports NV-387's Anti-Inflammatory Effects Could Combat Viral-Indu …
NV-387 is a remarkable antiviral drug, in that it not only attacks the virus, but also reduces inflammation, calming the human immune system so that untoward effects do not take place," said Anil R. Diwan, Ph.D., President and Chairman, adding, "NV-387 treatment reduces inflammation markers, particularly, IL-6, thereby protecting lungs. This reduction in inflammation and cyto-protective effect of NV-387 would also help minimize the risk of reawakening cancer, based on…
Rising Demand for Personal Injury Legal Services Amid Increasing Accident Claims
In many situations, negotiations with insurance companies are pursued before court proceedings are considered. Personal injury attorneys often act as intermediaries in these discussions, ensuring that offers are fairly assessed in relation to the damages sustained. If satisfactory agreements cannot be reached, the matter is presented before a court, where a judge or jury determines the outcome.
Personal injury law has been regarded as one of the most vital areas within…
Growing Awareness of Injury Risks Elevates Role of Car Accident Doctor
As awareness of accident-related injuries grows, Boise residents are taking a more proactive approach to their health following collisions.
Recovering from an auto accident involves more than just vehicle repairs-it also means addressing the physical injuries that often go unnoticed at first. For this reason, the role of a car accident doctor [https://www.pricechiropracticcenter.com/#:~:text=3-,Car%20Accident,-Have%20you%20been] has become increasingly important. In Boise, ID, more residents are realizing the long-term health risks associated with untreated…
Dog Grooming Standards Strengthened to Ensure Pet Health and Safety
In recent years, the importance of dog grooming has grown significantly, with veterinary professionals and pet owners alike recognizing its role in overall animal wellness.
Ensuring the health and happiness of pets requires much more than love and care at home-it also depends on professional grooming practices that meet the highest safety standards. In recent years, the importance of dog grooming [https://www.normandyblvdanimalhospital.com/#:~:text=lifespan%20of%20your-,dog,-or%20cat%20with] has grown significantly, with veterinary professionals and pet owners…
More Releases for Diabetic
Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring…
Leading Element Driving Change in the Diabetic Footwear Market in 2025: Rising D …
Which drivers are expected to have the greatest impact on the over the diabetic footwear market's growth?
The surge in people with diabetes will spur the expansion of the diabetic footwear market in the future. Diabetes, characterised by high blood sugar levels, is a long-term health issue. Diabetic footwear can prevent severe foot-related issues caused by diabetes and offer several advantages such as enhanced blood flow, ample space for the toes,…
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report.
On the basis of…
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and…
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025.
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282
Global Diabetic Socks Market: Factors Impacting the Market
The primary factors driving the growth of the global diabetic socks market are increasing…
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be…
